Alise Zagare
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alise Zagare has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Jens Christian Schwamborn
Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg
13 shared publications - Cláudia Saraiva
Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg
5 shared publications - Elisa Zuccoli
Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, 6, Avenue du Swing, L-4367 Belvaux, Luxembourg
3 shared publications - Giuseppe Arena
University of Luxembourg
3 shared publications - Kyriaki Barmpa
University of Luxembourg
3 shared publications - Rejko Krüger
Luxembourg Institute of Health
3 shared publications
Latest Publications
- Open Access
Replicative senescence of neural progenitors induces astrocyte senescence in 2D cultures and human midbrain organoids
Astrocyte senescence (astrosenescence) has emerged as a potential mechanism through which ageing may progressively impair glial homeostatic neuronal support and render the brain more vulnerable to neurodegenerative diseases such as Parkinson’s disease (PD). Yet human experimental models that specifically recapitulate astrosenescence within a PD-relevant genetic background are lacking. Here, we applied passage-induced replicative exhaustion to human iPSC-derived neuroepithelial stem cells (NESCs) from a healthy donor and LRRK2-G2019S PD patients to establish an in vitro midbrain ageing model. Extended passaging induced senescence-associated changes in NESCs, including reduced proliferative capacity, decreased cleaved caspase 3 (CC3) and telomerase mRNA expression, and DNA damage response (DDR) activation, while preserving differentiation potential. Astrocytes derived from aged progenitors showed an increase in SA-β-gal activity, loss of Lamin B1, DDR activation, and an altered mitochondrial morphology. In human midbrain organoids (hMOs), passage-induced ageing was associated with astrocyte-specific DDR activation and lipidomic remodelling. A multi-modal integrative analysis further revealed that, despite the variable penetrance of individual senescence-associated markers across lines, passage condition constitutes the primary discriminant of the collective cellular state, supporting the view that replicative senescence as a biological program is detectable only when individual readouts are aggregated across modalities. Together, this work establishes a human iPSC-based platform recapitulating key features of cellular senescence in both healthy and LRRK2-G2019S contexts and provides an in vitro platform to investigate the contribution of astrosenescence to PD-related neurodegeneration.
Open AccessReplicative senescence of neural progenitors induces astrocyte senescence in 2D cultures and human midbrain organoids
Astrocyte senescence (astrosenescence) has emerged as a potential mechanism through which ageing may progressively impair glial homeostatic neuronal support and render the brain more vulnerable to neurodegenerative diseases such as Parkinson’s disease (PD). Yet human experimental models that specifically recapitulate astrosenescence within a PD-relevant genetic background are lacking. Here, we applied passage-induced replicative exhaustion to human iPSC-derived neuroepithelial stem cells (NESCs) from a healthy donor and LRRK2-G2019S PD patients to establish an in vitro midbrain ageing model. Extended passaging induced senescence-associated changes in NESCs, including reduced proliferative capacity, decreased cleaved caspase 3 (CC3) and telomerase mRNA expression, and DNA damage response (DDR) activation, while preserving differentiation potential. Astrocytes derived from aged progenitors showed an increase in SA-β-gal activity, loss of Lamin B1, DDR activation, and an altered mitochondrial morphology. In human midbrain organoids (hMOs), passage-induced ageing was associated with astrocyte-specific DDR activation and lipidomic remodelling. A multi-modal integrative analysis further revealed that, despite the variable penetrance of individual senescence-associated markers across lines, passage condition constitutes the primary discriminant of the collective cellular state, supporting the view that replicative senescence as a biological program is detectable only when individual readouts are aggregated across modalities. Together, this work establishes a human iPSC-based platform recapitulating key features of cellular senescence in both healthy and LRRK2-G2019S contexts and provides an in vitro platform to investigate the contribution of astrosenescence to PD-related neurodegeneration.
- Open Access
- 25 March 2026
- Published by MDPI AG in Preprints.org
Brain Organoids in Parkinson’s Disease Drug Development: Human-Specific Models for Translational Discovery
Organoids are three-dimensional, stem-cell–derived cultures that mimic the structure and function of human tissues, providing improved physiological relevance over traditional 2D cell cultures and animal models. Their ability to replicate patient-specific biology makes them valuable for drug discovery, toxicity testing, and personalized medicine, enabling the prediction of individual responses to therapies. In the context of Parkinson’s disease (PD), midbrain organoids recapitulate key neurodegenerative phenotypes, including dopaminergic neuron loss, α-synuclein aggregation, metabolic dysfunction, and neuroinflammation, and have been successfully used to test various therapeutic strategies. Because PD is highly heterogeneous and current treatments remain largely symptomatic, there is an urgent need for improved preclinical models to overcome translational failures. Organoids offer a powerful solution to accelerate the development of effective disease-modifying treatments.
- 25 March 2026
- Published by MDPI AG in Preprints.org
Open AccessBrain Organoids in Parkinson’s Disease Drug Development: Human-Specific Models for Translational Discovery
Organoids are three-dimensional, stem-cell–derived cultures that mimic the structure and function of human tissues, providing improved physiological relevance over traditional 2D cell cultures and animal models. Their ability to replicate patient-specific biology makes them valuable for drug discovery, toxicity testing, and personalized medicine, enabling the prediction of individual responses to therapies. In the context of Parkinson’s disease (PD), midbrain organoids recapitulate key neurodegenerative phenotypes, including dopaminergic neuron loss, α-synuclein aggregation, metabolic dysfunction, and neuroinflammation, and have been successfully used to test various therapeutic strategies. Because PD is highly heterogeneous and current treatments remain largely symptomatic, there is an urgent need for improved preclinical models to overcome translational failures. Organoids offer a powerful solution to accelerate the development of effective disease-modifying treatments.
- Open Access
Autophagy Dysfunction in iPSCs-Derived Neurons and Midbrain Organoids Carrying a SNCA Triplication
Parkinson’s disease (PD), characterized by α-Synuclein aggregation and dopaminergic neuronal loss, has no current cure. Autophagy is critical for α-Synuclein clearance, yet its real-time dynamics remain challenging to assess in human-relevant systems. Here, we used live-cell imaging to assess autophagy within human neuronal cultures and midbrain organoids (hMOs) derived from induced pluripotent stem cells (iPSCs) of PD patients carrying a triplication of the α-Synuclein gene (3xSNCA). Using the LC3-Rosella dual-fluorescent reporter, we quantified autolysosomes dynamics in real time. In 3xSNCA neuronal cultures, we detected early autophagy defects. In 3xSNCA hMOs, reduced autolysosome area, increased total and phosphorylated α-Synuclein (pS129), and decreased electrophysiological activity were observed at 50 days of differentiation (DoD). By 70 DoD, autophagy impairment became more pronounced, overlapping with dopaminergic neuron loss. These findings support the use of human iPSCs-derived models to study autophagy dysfunction in PD and demonstrate a temporal correlation between impaired autophagy, α-Synuclein pathology and neuronal degeneration.
Open AccessAutophagy Dysfunction in iPSCs-Derived Neurons and Midbrain Organoids Carrying a SNCA Triplication
Parkinson’s disease (PD), characterized by α-Synuclein aggregation and dopaminergic neuronal loss, has no current cure. Autophagy is critical for α-Synuclein clearance, yet its real-time dynamics remain challenging to assess in human-relevant systems. Here, we used live-cell imaging to assess autophagy within human neuronal cultures and midbrain organoids (hMOs) derived from induced pluripotent stem cells (iPSCs) of PD patients carrying a triplication of the α-Synuclein gene (3xSNCA). Using the LC3-Rosella dual-fluorescent reporter, we quantified autolysosomes dynamics in real time. In 3xSNCA neuronal cultures, we detected early autophagy defects. In 3xSNCA hMOs, reduced autolysosome area, increased total and phosphorylated α-Synuclein (pS129), and decreased electrophysiological activity were observed at 50 days of differentiation (DoD). By 70 DoD, autophagy impairment became more pronounced, overlapping with dopaminergic neuron loss. These findings support the use of human iPSCs-derived models to study autophagy dysfunction in PD and demonstrate a temporal correlation between impaired autophagy, α-Synuclein pathology and neuronal degeneration.
- Open Access
Vascularized midbrain assembloids show neuroinflammation and dopaminergic neuron vulnerability in Parkinson’s Disease
The use of micro-physiological systems has rapidly risen in the last years due to their translatability and complex cellular composition. Human midbrain-specific organoids contain neuroectoderm-derived cell types and are suitable for brain region-specific disease modeling. However, the lack of vasculature in these systems reduces oxygenation and nutrient supply. Furthermore, neurovascular interactions cannot be studied, and disease phenotypes affecting vascular and neurovascular structures cannot be assessed. To overcome these limitations, in this work, we successfully incorporated a vascular network into midbrain organoids by fusion with vascular organoids. Midbrain-vascular assembloids are enriched in vascular cells and microglia. We observed a decrease in hypoxia and cell death in these assembloids. Furthermore, microglia and endothelial cells increased their morphological complexity. Assembloids derived from a Parkinson’s disease patient carrying a LRRK2-G2019S mutation displayed a pro-inflammatory phenotype and altered electrophysiological properties. Midbrain-vascular assembloids increase the midbrain model complexity and allow for neuroinflammation studies in Parkinson’s disease.
Open AccessVascularized midbrain assembloids show neuroinflammation and dopaminergic neuron vulnerability in Parkinson’s Disease
The use of micro-physiological systems has rapidly risen in the last years due to their translatability and complex cellular composition. Human midbrain-specific organoids contain neuroectoderm-derived cell types and are suitable for brain region-specific disease modeling. However, the lack of vasculature in these systems reduces oxygenation and nutrient supply. Furthermore, neurovascular interactions cannot be studied, and disease phenotypes affecting vascular and neurovascular structures cannot be assessed. To overcome these limitations, in this work, we successfully incorporated a vascular network into midbrain organoids by fusion with vascular organoids. Midbrain-vascular assembloids are enriched in vascular cells and microglia. We observed a decrease in hypoxia and cell death in these assembloids. Furthermore, microglia and endothelial cells increased their morphological complexity. Assembloids derived from a Parkinson’s disease patient carrying a LRRK2-G2019S mutation displayed a pro-inflammatory phenotype and altered electrophysiological properties. Midbrain-vascular assembloids increase the midbrain model complexity and allow for neuroinflammation studies in Parkinson’s disease.
- Open Access
Parkinson’s disease microglia induce endogenous α-synuclein pathology in patient-specific midbrain organoids
The accumulation of misfolded α-synuclein and the loss of dopaminergic neurons are hallmarks of Parkinson’s disease (PD), contributing to the development of synucleinopathies. Although considerable progress has been made in understanding α-synuclein’s role in PD pathology, the precise mechanisms involved remain unclear. Human midbrain organoids (hMOs) have emerged as valuable models for studying PD, yet the lack of microglia limits the ability to investigate neuroimmune interactions. Recent studies show that integrating microglia into hMOs enhances neuronal maturation and functionality. Here, we generated a human midbrain assembloid model by incorporating iPSC-derived microglia into midbrain organoids from healthy control individuals and a PD patient carrying the SNCA triplication (3xSNCA) mutation. Our results show that 3xSNCA microglia alone are sufficient to induce early, endogenous formation of phosphorylated α-synuclein (pS129) pathology in the absence of exogenous fibril seeding. This PD-pathology emerged as early as day 50 of culture and was not observed in models lacking microglia. These findings highlight a critical role for patient-derived microglia in driving α- synuclein pathology and provide a physiologically relevant platform for studying early neuroimmune mechanisms in PD and testing potential therapeutic strategies.
Open AccessParkinson’s disease microglia induce endogenous α-synuclein pathology in patient-specific midbrain organoids
The accumulation of misfolded α-synuclein and the loss of dopaminergic neurons are hallmarks of Parkinson’s disease (PD), contributing to the development of synucleinopathies. Although considerable progress has been made in understanding α-synuclein’s role in PD pathology, the precise mechanisms involved remain unclear. Human midbrain organoids (hMOs) have emerged as valuable models for studying PD, yet the lack of microglia limits the ability to investigate neuroimmune interactions. Recent studies show that integrating microglia into hMOs enhances neuronal maturation and functionality. Here, we generated a human midbrain assembloid model by incorporating iPSC-derived microglia into midbrain organoids from healthy control individuals and a PD patient carrying the SNCA triplication (3xSNCA) mutation. Our results show that 3xSNCA microglia alone are sufficient to induce early, endogenous formation of phosphorylated α-synuclein (pS129) pathology in the absence of exogenous fibril seeding. This PD-pathology emerged as early as day 50 of culture and was not observed in models lacking microglia. These findings highlight a critical role for patient-derived microglia in driving α- synuclein pathology and provide a physiologically relevant platform for studying early neuroimmune mechanisms in PD and testing potential therapeutic strategies.
- Open Access
Reproducibility of PD patient-specific midbrain organoid data for in vitro disease modelling
Midbrain organoids are advanced in vitro cellular models for disease modelling. They have been used successfully over the past decade for Parkinson’s disease (PD) research and drug development. The three-dimensional structure and multicellular composition allow disease research under more physiological conditions than is possible with conventional 2D cellular models. However, there are concerns in the field regarding the organoid batch-to-batch variability and thus the reproducibility of the results. In this manuscript, we generate multiple independent midbrain organoid batches derived from healthy individuals or GBA-N370S mutation-carrying PD patients to evaluate the reproducibility of the GBA-N370S mutation-associated PD transcriptomic and metabolic signature as well as selected protein abundance. Our analysis shows that GBA-PD-associated phenotypes are reproducible across organoid generation batches and time points. This proves that midbrain organoids are not only suitable for PD in vitro modelling, but also represent robust and highly reproducible cellular models.
Open AccessReproducibility of PD patient-specific midbrain organoid data for in vitro disease modelling
Midbrain organoids are advanced in vitro cellular models for disease modelling. They have been used successfully over the past decade for Parkinson’s disease (PD) research and drug development. The three-dimensional structure and multicellular composition allow disease research under more physiological conditions than is possible with conventional 2D cellular models. However, there are concerns in the field regarding the organoid batch-to-batch variability and thus the reproducibility of the results. In this manuscript, we generate multiple independent midbrain organoid batches derived from healthy individuals or GBA-N370S mutation-carrying PD patients to evaluate the reproducibility of the GBA-N370S mutation-associated PD transcriptomic and metabolic signature as well as selected protein abundance. Our analysis shows that GBA-PD-associated phenotypes are reproducible across organoid generation batches and time points. This proves that midbrain organoids are not only suitable for PD in vitro modelling, but also represent robust and highly reproducible cellular models.
- Open Access
- 17 April 2025
- Published by Springer Nature in npj Systems Biology and Applications
- Vol. 11 (1) , 1-15
MIRO1 mutation leads to metabolic maladaptation resulting in Parkinson’s disease-associated dopaminergic neuron loss
MIRO1 is a mitochondrial outer membrane protein important for mitochondrial distribution, dynamics and bioenergetics. Over the last decade, evidence has pointed to a link between MIRO1 and Parkinson’s disease (PD) pathogenesis. Moreover, a heterozygous MIRO1 mutation (p.R272Q) was identified in a PD patient, from which an iPSC-derived midbrain organoid model was derived, showing MIRO1 mutant-dependent selective loss of dopaminergic neurons. Herein, we use patient-specific iPSC-derived midbrain organoids carrying the MIRO1 p.R272Q mutation to further explore the cellular and molecular mechanisms involved in dopaminergic neuron degeneration. Using single-cell RNA sequencing (scRNAseq) analysis and metabolic modeling we show that the MIRO1 p.R272Q mutation affects the dopaminergic neuron developmental path leading to metabolic deficits and disrupted neuron-astrocyte metabolic crosstalk, which might represent an important pathogenic mechanism leading to their loss.
- 17 April 2025
- Published by Springer Nature in npj Systems Biology and Applications
- Vol. 11 (1) , 1-15
Open AccessMIRO1 mutation leads to metabolic maladaptation resulting in Parkinson’s disease-associated dopaminergic neuron loss
MIRO1 is a mitochondrial outer membrane protein important for mitochondrial distribution, dynamics and bioenergetics. Over the last decade, evidence has pointed to a link between MIRO1 and Parkinson’s disease (PD) pathogenesis. Moreover, a heterozygous MIRO1 mutation (p.R272Q) was identified in a PD patient, from which an iPSC-derived midbrain organoid model was derived, showing MIRO1 mutant-dependent selective loss of dopaminergic neurons. Herein, we use patient-specific iPSC-derived midbrain organoids carrying the MIRO1 p.R272Q mutation to further explore the cellular and molecular mechanisms involved in dopaminergic neuron degeneration. Using single-cell RNA sequencing (scRNAseq) analysis and metabolic modeling we show that the MIRO1 p.R272Q mutation affects the dopaminergic neuron developmental path leading to metabolic deficits and disrupted neuron-astrocyte metabolic crosstalk, which might represent an important pathogenic mechanism leading to their loss.
- Open Access
- 31 March 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 11 (1) , 1-14
Deciphering shared molecular dysregulation across Parkinson’s disease variants using a multi-modal network-based data integration and analysis
Parkinson’s disease (PD) is a progressive neurodegenerative disorder with no effective treatment. Advances in neuroscience and systems biomedicine now enable the use of complex patient-specific in vitro disease models and cutting-edge computational tools for data integration, enhancing our understanding of complex PD mechanisms. To explore common biomedical features across monogenic PD forms, we developed a knowledge graph (KG) by integrating previously published high-content imaging and RNA sequencing data of PD patient-specific midbrain organoids harbouring LRRK2-G2019S, SNCA triplication, GBA-N370S or MIRO1-R272Q mutations with publicly available biological data. Furthermore, we generated a single-cell RNA sequencing dataset of midbrain organoids derived from idiopathic PD patients (IPD) to stratify IPD patients within the spectrum of monogenic forms of PD. Despite the high degree of PD heterogeneity, we found that common transcriptomic dysregulation in monogenic PD forms is reflected in glial cells of IPD patient midbrain organoids. In addition, dysregulation in ROBO signalling might be involved in shared pathophysiology between monogenic PD and IPD cases.
- 31 March 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 11 (1) , 1-14
Open AccessDeciphering shared molecular dysregulation across Parkinson’s disease variants using a multi-modal network-based data integration and analysis
Parkinson’s disease (PD) is a progressive neurodegenerative disorder with no effective treatment. Advances in neuroscience and systems biomedicine now enable the use of complex patient-specific in vitro disease models and cutting-edge computational tools for data integration, enhancing our understanding of complex PD mechanisms. To explore common biomedical features across monogenic PD forms, we developed a knowledge graph (KG) by integrating previously published high-content imaging and RNA sequencing data of PD patient-specific midbrain organoids harbouring LRRK2-G2019S, SNCA triplication, GBA-N370S or MIRO1-R272Q mutations with publicly available biological data. Furthermore, we generated a single-cell RNA sequencing dataset of midbrain organoids derived from idiopathic PD patients (IPD) to stratify IPD patients within the spectrum of monogenic forms of PD. Despite the high degree of PD heterogeneity, we found that common transcriptomic dysregulation in monogenic PD forms is reflected in glial cells of IPD patient midbrain organoids. In addition, dysregulation in ROBO signalling might be involved in shared pathophysiology between monogenic PD and IPD cases.
- Open Access
- 6 February 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 148 (10) , 3607-3622
Parkinson’s disease mutant Miro1 causes mitochondrial dysfunction and dopaminergic neuron loss
The complex and heterogeneous nature of Parkinson's disease (PD) is still not fully understood. However, increasing evidence supports mitochondrial impairment as a major driver of neurodegeneration. Miro1, a mitochondrial GTPase encoded by the RHOT1 gene, is involved in mitochondrial transport, mitophagy and mitochondrial calcium buffering, and is therefore essential for maintaining mitochondrial homeostasis. Recently, Miro1 has been linked genetically and pathophysiologically to PD, further supported by the identification of heterozygous variants of Miro1 in patients. Herein, we used patient-derived cellular models alongside knock-in mice to investigate Miro1-dependent pathophysiological processes and molecular mechanisms underlying neurodegeneration in PD. Experimental work performed in induced pluripotent stem cell (iPSC)-derived models, including midbrain organoids and dopaminergic neuronal cell cultures from a PD patient carrying the p.R272Q Miro1 mutation as well as healthy and isogenic controls, indicated that the p.R272Q Miro1 mutation leads to increased oxidative stress, disrupted mitochondrial bioenergetics and altered cellular metabolism. These changes were accompanied by increased α-synuclein levels and a significant reduction of dopaminergic neurons. Moreover, the p.R272Q Miro1 mutation—located in the calcium-binding domain of the GTPase—disrupted calcium homeostasis, resulting in calcium-dependent activation of calpain proteases and the subsequent cleavage of α-synuclein. Knock-in mice expressing p.R285Q Miro1 (the murine orthologue of the human p.R272Q mutation) displayed accumulation of phosphorylated α-synuclein in the striatum and a significant loss of dopaminergic neurons in the substantia nigra pars compacta, accompanied by behavioural alterations. These findings demonstrate that mutant Miro1 is sufficient to comprehensively model PD-relevant phenotypes in vitro and in vivo, reinforcing its pivotal role in PD pathogenesis.
- 6 February 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 148 (10) , 3607-3622
Open AccessParkinson’s disease mutant Miro1 causes mitochondrial dysfunction and dopaminergic neuron loss
The complex and heterogeneous nature of Parkinson's disease (PD) is still not fully understood. However, increasing evidence supports mitochondrial impairment as a major driver of neurodegeneration. Miro1, a mitochondrial GTPase encoded by the RHOT1 gene, is involved in mitochondrial transport, mitophagy and mitochondrial calcium buffering, and is therefore essential for maintaining mitochondrial homeostasis. Recently, Miro1 has been linked genetically and pathophysiologically to PD, further supported by the identification of heterozygous variants of Miro1 in patients. Herein, we used patient-derived cellular models alongside knock-in mice to investigate Miro1-dependent pathophysiological processes and molecular mechanisms underlying neurodegeneration in PD. Experimental work performed in induced pluripotent stem cell (iPSC)-derived models, including midbrain organoids and dopaminergic neuronal cell cultures from a PD patient carrying the p.R272Q Miro1 mutation as well as healthy and isogenic controls, indicated that the p.R272Q Miro1 mutation leads to increased oxidative stress, disrupted mitochondrial bioenergetics and altered cellular metabolism. These changes were accompanied by increased α-synuclein levels and a significant reduction of dopaminergic neurons. Moreover, the p.R272Q Miro1 mutation—located in the calcium-binding domain of the GTPase—disrupted calcium homeostasis, resulting in calcium-dependent activation of calpain proteases and the subsequent cleavage of α-synuclein. Knock-in mice expressing p.R285Q Miro1 (the murine orthologue of the human p.R272Q mutation) displayed accumulation of phosphorylated α-synuclein in the striatum and a significant loss of dopaminergic neurons in the substantia nigra pars compacta, accompanied by behavioural alterations. These findings demonstrate that mutant Miro1 is sufficient to comprehensively model PD-relevant phenotypes in vitro and in vivo, reinforcing its pivotal role in PD pathogenesis.
- Open Access
- 24 January 2025
- Published by Wiley in Parkinson's Disease
- Vol. 2025 (1) , 5149071
Cystatin C Secretion in Blood Derivatives and Cellular Models of Idiopathic Parkinson’s Disease
Parkinson’s disease is an age‐related progressive neurodegenerative disorder. A large majority of Parkinson’s disease patients have an unknown etiology, which is classified as idiopathic Parkinson’s disease. Generating disease models directly from idiopathic Parkinson’s disease patients may improve the understanding of the disease pathology. Both neuroprotective and neurodegenerative roles have been suggested for cystatin C in neurodegenerative disease. In Parkinson’s disease, investigations assessing cystatin C levels in different types of biospecimens such as blood, cerebrospinal fluid, and in vitro models have had conflicting results. We present a study assessing cystatin C levels in different biospecimen types originating from the same subjects. Using a sandwich ELISA, we compared cystatin C concentration in blood derivatives (plasma and serum) and culture media of derived models (stem cells, neuroepithelial stem cells, and midbrain organoids) of three idiopathic Parkinson’s disease and three age‐matched healthy control subjects with the same CST3 genotype. Genotyping analyses confirmed that all subjects were homozygous AA. The identity of the derived models was confirmed using immunohistochemical staining. Secreted cystatin C concentration was measured in each biospecimen tested. No statistically significant differences in cystatin C concentrations were found between the subjects in any of the biospecimen types. As a personalized marker, a higher cystatin C concentration was shown for some individual patients in the culture medium of midbrain organoids, suggesting a potential involvement in Parkinson’s disease physiopathology. This proof of concept demonstrates that cystatin C is secreted by various idiopathic Parkinson’s disease cell models, including midbrain organoids, which in turn suggests that cystatin C secretion by midbrain organoids might be pertinent in neurodegenerative disease research.
- 24 January 2025
- Published by Wiley in Parkinson's Disease
- Vol. 2025 (1) , 5149071
Open AccessCystatin C Secretion in Blood Derivatives and Cellular Models of Idiopathic Parkinson’s Disease
Parkinson’s disease is an age‐related progressive neurodegenerative disorder. A large majority of Parkinson’s disease patients have an unknown etiology, which is classified as idiopathic Parkinson’s disease. Generating disease models directly from idiopathic Parkinson’s disease patients may improve the understanding of the disease pathology. Both neuroprotective and neurodegenerative roles have been suggested for cystatin C in neurodegenerative disease. In Parkinson’s disease, investigations assessing cystatin C levels in different types of biospecimens such as blood, cerebrospinal fluid, and in vitro models have had conflicting results. We present a study assessing cystatin C levels in different biospecimen types originating from the same subjects. Using a sandwich ELISA, we compared cystatin C concentration in blood derivatives (plasma and serum) and culture media of derived models (stem cells, neuroepithelial stem cells, and midbrain organoids) of three idiopathic Parkinson’s disease and three age‐matched healthy control subjects with the same CST3 genotype. Genotyping analyses confirmed that all subjects were homozygous AA. The identity of the derived models was confirmed using immunohistochemical staining. Secreted cystatin C concentration was measured in each biospecimen tested. No statistically significant differences in cystatin C concentrations were found between the subjects in any of the biospecimen types. As a personalized marker, a higher cystatin C concentration was shown for some individual patients in the culture medium of midbrain organoids, suggesting a potential involvement in Parkinson’s disease physiopathology. This proof of concept demonstrates that cystatin C is secreted by various idiopathic Parkinson’s disease cell models, including midbrain organoids, which in turn suggests that cystatin C secretion by midbrain organoids might be pertinent in neurodegenerative disease research.